Palvella Therapeutics, Inc (PVLA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Palvella Therapeutics, Inc stock (PVLA) is currently trading at $120.39. Analyst consensus price target for PVLA is $224.27. WallStSmart rates PVLA as Sell.
- PVLA PE ratio analysis and historical PE chart
- PVLA PS ratio (Price-to-Sales) history and trend
- PVLA intrinsic value — DCF, Graham Number, EPV models
- PVLA stock price prediction 2025 2026 2027 2028 2029 2030
- PVLA fair value vs current price
- PVLA insider transactions and insider buying
- Is PVLA undervalued or overvalued?
- Palvella Therapeutics, Inc financial analysis — revenue, earnings, cash flow
- PVLA Piotroski F-Score and Altman Z-Score
- PVLA analyst price target and Smart Rating
Palvella Therapeutics, Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Palvella Therapeutics, Inc (PVLA) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
Palvella Therapeutics, Inc (PVLA) Key Strengths (1)
80.66% of shares held by major funds and institutions
Supporting Valuation Data
Palvella Therapeutics, Inc (PVLA) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 41.5x book value
Small-cap company with higher risk but more growth potential
Palvella Therapeutics, Inc (PVLA) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Book, Market Cap. Some valuation metrics including Price/Book (41.45) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -301.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -301.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PVLA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Palvella Therapeutics, Inc (PVLA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Palvella Therapeutics, Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -8M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Palvella Therapeutics, Inc.
Bottom Line
Palvella Therapeutics, Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:06:46 AM
About Palvella Therapeutics, Inc(PVLA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Palvella Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases, particularly those resulting from specific gene mutations. The company's lead investigational product addresses pachyonychia congenita, targeting critical unmet medical needs within this specialized patient demographic. Leveraging a strong gene therapy foundation, Palvella is dedicated to expanding its pipeline with transformative solutions aimed at significantly improving patient quality of life. With a strategic emphasis on research and development, the company is poised to make a meaningful impact in the rare disease treatment arena.